CARE-CP(测试胸痛患者的心血管动态快速评估) (CARE-CP)
The goal of this study is to determine if rapid outpatient evaluation vs hospitalization management is the best strategy (based on patient-centered measures and safe, equitable, and efficient resource use) for evaluating patients with acute chest pain who are at moderate risk for acute coronary syndrome (ACS). Patients will be randomized in the Emergency Department to either an outpatient evaluation (CARE-CP) or hospitalization evaluation for their symptoms.
研究概览
详细说明
Current care patterns for the 7 million patients visiting Emergency Departments (EDs) in the United States with chest pain are heterogeneous and not sustainable from a healthcare quality or economic perspective. Chest pain is the second most common cause of ED visits and the most common reason for short-stay hospitalizations. During these hospitalizations patients undergo in-depth evaluations (stress testing, computed tomography coronary angiography, or invasive angiography), but ultimately <10% are diagnosed with acute coronary syndrome (ACS). These evaluations cost $3 billion annually and strain health system resources without clear evidence of improved health outcomes or patient experience. The preliminary data suggest that moderate risk patients (35% of patients with chest pain) can be safely managed as outpatients using a cardiovascular ambulatory rapid evaluation (CARE-CP) strategy as an alternative to hospitalization. In the CARE-CP strategy, patients are discharged from the ED and receive outpatient clinic follow-up within 72 hours focused on medical management for cardiovascular risk factors (e.g., hypertension, diabetes) and determining whether further cardiac testing is needed. This strategy aims to enhance patient-centered outcomes while safely and equitably decreasing hospital resource utilization. However, equipoise exists between outpatient and hospitalization strategies for moderate risk patients. There is a paucity of prospective data evaluating the efficacy and patient-centeredness of outpatient chest pain evaluation strategies in moderate risk patients. Thus, it is unclear whether use of an outpatient chest pain management strategy (CARE-CP) will safely reduce healthcare utilization and be preferred by patients compared to a traditional hospitalization strategy. To address this key evidence gap, the study proposes the first prospective multisite randomized trial testing outpatient vs hospitalization strategies in moderate risk patients. The research teams will randomize 502 patients 1:1 to the CARE-CP or hospitalization management arms at three ED sites with a history of high recruitment rates and productive collaborations in cardiovascular clinical trials. The primary outcome will be hospital-free days (HFD) over a 30-day period. This novel trial addresses a key evidence gap by providing guidance on how best to evaluate moderate risk ED patients with acute chest pain. Without this guidance care patterns are likely to remain heterogeneous, inefficient, non-patient-centered, and unguided by the highest level of evidence. We hypothesize that data from this trial will support widespread implementation of a CARE-CP strategy, which could improve the quality and value of care for millions of patients in the U.S. and beyond.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Lauren Koehler
- 电话号码:336-716-4646
- 邮箱:Lauren.Koehler@Advocatehealth.org
学习地点
-
-
Michigan
-
Detroit、Michigan、美国、48202
- 招聘中
- Henry Ford Hospital
-
-
North Carolina
-
Charlotte、North Carolina、美国、28203
- 招聘中
- Carolinas Medical Center
-
Winston-Salem、North Carolina、美国、27157
- 招聘中
- Wake Forest University Health Sciences
-
接触:
- Lauren Koehler
- 邮箱:Lauren.Koehler@Advocatehealth.org
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Age ≥21 years old
-
Chest pain or Symptoms of acute coronary syndrome (ACS)
-
Moderate risk of ACS (all of the below)
-
Hear Score 4-6
-
Non-Ischemic electrocardiogram (ECG)
-
Two Troponin measures < Sex-Specific Upper Reference Limit
- Women <15 pg/ml
- Men <20 pg/ml
-
No prior coronary artery disease (CAD)
- No Prior Myocardial Infarction (MI)
- No Prior Coronary Revascularization Procedures
- No Patients with ≥ 70% Obstructive Coronary Disease
Exclusion Criteria:
- ST Elevation Myocardial Infarction (STEMI) Activation
- ST Changes or new T-wave inversions ≥1mm on ECG
- Any Elevated Troponin Measure (Based on Sex-Specific 99th Percentile)
- Serial change between Troponin Measures (Delta) ≥5 pg/mL
- Stress Echocardiography, Nuclear Stress Test, Stress ECG, Stress Cardiac MRI, Coronary CT Angiogram (CCTA), Invasive Coronary Angiography (Cardiac Cath) within 1 year
- "Clean" CCTA or Cardiac Cath (0% stenosis in all vessels) within the past 2 years
- Chest Trauma
- Pregnancy
- Life Expectancy < 1 year
- Other comorbid conditions requiring hospitalization
- Unstable Vitals (Blood Pressure <90, Heart Rate >120 or <50, O2 Sat <90%)
- End Stage Renal Disease; Dialysis or estimated glomerular filtration rate (eGFR) <30 mL/min
- Transfers From Another Hospital
- Non-English Speaking
- Prisoners
- Prior Enrollment
- Already Enrolled in Other Interventional Trial
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
其他:Outpatient Evaluation
Patients randomized to this arm are discharged and receive outpatient evaluation, or cardiovascular ambulatory rapid evaluation (CARE), focused on medical management for cardiovascular risk factors (e.g. hypertension) within 72 hours of Emergency Department discharge. |
Subjects will receive an outpatient evaluation within 72 of being discharged from the ED.
其他名称:
|
|
其他:Hospitalization Evaluation
Patients randomized to this arm receive evaluation for their symptoms in a hospital ward, observation unit, or emergency department boarding. |
Patients randomized to this arm receive evaluation for their symptoms in a hospital ward, observation unit, or emergency department boarding. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Hospital-free days (HFD) at 30-days post-randomization
大体时间:Day 30
|
Time spent in a hospital setting at 30 days post-randomization will be measured and subtracted from time spent outside the hospital. Hospital time is broadly defined, based on a patient-centered definition of cumulative time spent in the ED, observation unit, or hospital ward. Consistent with prior trials, patients who experience death during the follow-up period are assigned zero HFDs. |
Day 30
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Hospital-free days (HFD) at 1-year post-randomization
大体时间:Year 1
|
Time spent in a hospital setting at 1 year post-randomization will be measured and subtracted from time spent outside the hospital. Hospital time is broadly defined, based on a patient-centered definition of cumulative time spent in the ED, observation unit, or hospital ward. Consistent with prior trials, patients who experience death during the follow-up period are assigned zero HFDs. |
Year 1
|
|
Cardiovascular Hospital-free days (HFD) at 30-days post-randomization
大体时间:Day 30
|
Rates of cardiovascular rehospitalizations at 30-days post-randomization will be analyzed between the two treatment arms. |
Day 30
|
|
Cardiovascular Hospital-free days (HFD) at 1 year post-randomization
大体时间:Year 1
|
Rates of cardiovascular rehospitalizations at 1 year post-randomization will be analyzed between the two treatment arms. |
Year 1
|
|
Rate of noninvasive cardiac testing at 30-days post-randomization
大体时间:Day 30
|
The rates of noninvasive testing (stress testing and coronary computed tomography angiography), at 30-days post-randomization will be analyzed between the two treatment arms. |
Day 30
|
|
Rate of noninvasive cardiac testing at 1 year post-randomization
大体时间:Year 1
|
The rates of noninvasive testing (stress testing and coronary computed tomography angiography), at 1 year post-randomization will be analyzed between the two treatment arms. |
Year 1
|
|
Rate of invasive cardiac testing at 30-days post-randomization
大体时间:Day 30
|
The rates of invasive testing (coronary angiography), at 30-days post-randomization will be analyzed between the two treatment arms. |
Day 30
|
|
Rate of invasive cardiac testing at 1 year post-randomization
大体时间:Year 1
|
The rates of invasive testing (coronary angiography), at 1 year post-randomization will be analyzed between the two treatment arms. |
Year 1
|
|
Cardiovascular repeat ED visits at 30-days post-randomization
大体时间:Day 30
|
The rates of Cardiovascular repeat ED visits at 30-days post-randomization will be analyzed between the two treatment arms.The ED visit will be categorized as cardiovascular if a cardiac procedure is performed, the primary reason for admission is possible ACS, or a discharge diagnosis relates to chest pain, MI, ACS, heart failure, or other cardiac disease (e.g., dysrhythmia, pericardial disease, etc.). Cardiac procedures include stress testing, noninvasive and invasive coronary angiography, coronary revascularization, and pacemaker or defibrillator insertion. |
Day 30
|
|
Cardiovascular repeat ED visits at 1 year post-randomization
大体时间:Year 1
|
The rates of Cardiovascular repeat ED visits at 1 year post-randomization will be analyzed between the two treatment arms.The ED visit will be categorized as cardiovascular if a cardiac procedure is performed, the primary reason for admission is possible ACS, or a discharge diagnosis relates to chest pain, MI, ACS, heart failure, or other cardiac disease (e.g., dysrhythmia, pericardial disease, etc.). Cardiac procedures include stress testing, noninvasive and invasive coronary angiography, coronary revascularization, and pacemaker or defibrillator insertion. |
Year 1
|
|
Cardiovascular rehospitalizations at 30-days post-randomization
大体时间:Day 30
|
The rates of Cardiovascular rehospitalizations at 30-days post-randomization will be analyzed between the two treatment arms.The rehospitalization will be categorized as cardiovascular if a cardiac procedure is performed, the primary reason for admission is possible ACS, or a discharge diagnosis relates to chest pain, MI, ACS, heart failure, or other cardiac disease (e.g., dysrhythmia, pericardial disease, etc.). Cardiac procedures include stress testing, noninvasive and invasive coronary angiography, coronary revascularization, and pacemaker or defibrillator insertion. |
Day 30
|
|
Cardiovascular rehospitalizations at 1 year post-randomization
大体时间:Year 1
|
The rates of Cardiovascular rehospitalizations at 1 year post-randomization will be analyzed between the two treatment arms.The rehospitalization will be categorized as cardiovascular if a cardiac procedure is performed, the primary reason for admission is possible ACS, or a discharge diagnosis relates to chest pain, MI, ACS, heart failure, or other cardiac disease (e.g., dysrhythmia, pericardial disease, etc.). Cardiac procedures include stress testing, noninvasive and invasive coronary angiography, coronary revascularization, and pacemaker or defibrillator insertion. |
Year 1
|
|
Patient satisfaction (SAPS questionnaire)
大体时间:Day 30
|
Satisfaction will be assessed using the Short Assessment of Patient Satisfaction (SAPS). A patient satisfaction survey will be sent that evaluates clinician communication, participation in medical decision-making, respect by the clinician, clinician carefulness, time with the clinician, and treatment effect, in any service setting on a five-point Likert scale from "very dissatisfied" to "very satisfied". Scores from each item are summed and range from 0 (extremely dissatisfied) to 28 (extremely satisfied). |
Day 30
|
|
Patient experience (GS-PEQ instrument)
大体时间:Day 30
|
Experience will be measured using the Generic Short Patient Experience Questionnaire (GS-PEQ). A patient experience survey will also be sent out to evaluate which assesses timeliness and organization of medical services, confidence in the clinician and treatment, patient involvement in decision-making, clinician communication, patient outcomes, and incorrect treatment on a 5-point Likert-scale from "not at all" to "to a very large extent" and one question (on wait times) scored on a 4-point Likert scale from "no" to "yes, way too long. A mean score can be calculated for each patient, with higher scores indicating better experience. |
Day 30
|
|
Out-of-pocket cost (based on billing data)
大体时间:Day 30
|
Patient satisfaction, patient experience, and out-of-pocket costs will be measured in all trial participants. Financial records will be utilized from each site to determine patient billing, including the amount covered by insurance vs. patient responsibility. Each item will be measured in U.S. dollars and summed for total cost. |
Day 30
|
|
Drivers of Patient Satisfaction and Experience (Qualitative)
大体时间:Day 30
|
A subset of 100 patients (50 from each arm) will be purposively selected to ensure diversity in sex, race, ethnicity, socioeconomic status (SES), and health literacy for 30-minute semi-structured phone interviews to determine key drivers of patient satisfaction and experience. We will use an explanatory sequential mixed-methods design, in which participants' quantitative data will guide the collection and analysis of their qualitative data.These data will provide key context and meaning to the patient's quantitative response regarding patient satisfaction, experience, and out-of-pocket cost. |
Day 30
|
合作者和调查者
调查人员
- 首席研究员:Simon Mahler, MD, MS、Wake Forest University Health Sciences
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.